AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis

Forty students will receive $2,500 scholarships for the 2013-2014 school year, – Apply through Friday, June 14 at www.AbbVieCFScholarship.com,

NORTH CHICAGO, Ill., May 1, 2013 — /PRNewswire/ — AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the AbbVie CF Scholarship for the 2013-2014 academic school year.

Previously known as the CFCareForward Scholarship, the AbbVie CF Scholarship was established 21 years ago to honor young adults with CF as they pursue goals of higher education. In 2013, forty students will be awarded $2,500 each based on outstanding academic record, extracurricular activities and creativity. Applications will be accepted through Friday, June 14.

“AbbVie is proud to be able to provide this scholarship to exceptional students living with CF,” said Jim Hynd, divisional vice president, Cardiovascular Care, Metabolics and GI Care, AbbVie. “For more than 20 years, we have been inspired by the CF scholars who continually demonstrate that it is possible to achieve personal and academic success while living with a chronic disease.”

Later this year, in honor of the 21st year of the scholarship program, the forty AbbVie CF Scholarship recipients will have the opportunity to compete for one of two Thriving Student Scholarships (based on level of study) resulting in a total scholarship award of $21,000 each.

It is not necessary for scholarship applicants to have taken, currently take, or intend to take in the future, any medicine or product marketed by AbbVie and this is not a consideration in the selection criteria. More information about the AbbVie CF Scholarship criteria and application can be found at www.AbbVieCFScholarship.com.

About Cystic Fibrosis Approximately 30,000 children and adults in the United States are living with CF, an inherited chronic disease that affects the lungs and digestive systems. More than 70 percent of people with CF are diagnosed by age two. Today, more than 45 percent of people living with CF are aged 18 or older.  In patients with CF, a thick, sticky mucus is produced in certain organs throughout the body, most commonly the lungs and digestive system. The mucus build-up in the lungs can cause difficulty breathing and may lead to life-threatening lung infections. In the digestive system, the thick mucus may prevent proper food digestion.

About AbbVie AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Guest Blog by Mark A. Levine: CF: Teaching What Text Books Don’t

I always wanted to be a teacher. In some respects, I already am. As an engineering manager for Chrysler, I teach all the time. Outside my full-time job, I have my own ACT math and science tutoring business. I also used to help my kids with their homework before they became smarter than Continue reading Guest Blog by Mark A. Levine: CF: Teaching What Text Books Don’t

U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios’ Novel Biologic Candidate for Pseudomonas aeruginosa

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), and KaloBios Pharmaceuticals (KBIO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sanofi Pasteur for the investigation of KB001A, an Continue reading U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios’ Novel Biologic Candidate for Pseudomonas aeruginosa

Savara Pharma begins phase II study of AeroVanc for MRSA lung infection in CF patients

Savara Pharmaceuticals, an emerging specialty pharmaceutical company, has started study drug treatment in a Phase 2 clinical trial evaluating the safety and efficacy of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis Continue reading Savara Pharma begins phase II study of AeroVanc for MRSA lung infection in CF patients

Check out Genentech’s new Muck Busters iPhone game

Genentech has just launched Muck Busters, which is an iPhone game that is not only fun to play, but also brings an educational component to CF patients and caregivers through a very clever game design. Users navigate a colorful world battling stubborn enemies including bacteria, white blood Continue reading Check out Genentech’s new Muck Busters iPhone game

CF Podcast #120: The Hatfield Brothers, Brett and Brennan – Being Compliant with CF

In this episode, we talk with Brett and Brennan Hatfield, both of whom are brothers and enjoying high school in Omaha, Nebraska. Bret is 15, Brennan is 17, and both are living, breathing and succeeding with cystic fibrosis. http://www.youtube.com/watch?v=-T5FZlKalZE&feature=share

• Brett and Brennan were diagnosed with cystic fibrosis when they were four years old. Continue reading CF Podcast #120: The Hatfield Brothers, Brett and Brennan – Being Compliant with CF

One Year Post Transplant: Where is Jerry Now?

Just one year ago on April 18, 2012, Jerry underwent a double-lung transplant surgery, and was back home interacting with the CF community only fifteen days later. Three months after his transplant, Jerry ran in Boomer’s CF Run to Breathe 10K in Central Park with his surgeon. Jerry’s Continue reading One Year Post Transplant: Where is Jerry Now?

A must-read blog in NY Times Opinionator column

This blog was written by a woman who dated and then married a young man who had CF. She has written about this in The Modern Love column in the NY Times as well as just had a memoir published about her life with this man. It is so moving and well-written, I highly recommend at least reading her blog and then possibly purchasing her memoir titled, My Foreign Cities. This might not only interest those whose lives have been touched by those around them who have CF but those with CF as well.

The Ways I’ve Worried By Elizabeth Scarboro

Recently, I found myself lying in bed, trying to sleep, a common occurrence. I had forgotten to call my mom back earlier, and I now pictured her standing in her kitchen. Then the next second she had aged 20 years in my mind, she needed help and I worried about where she and my dad would live, since my husband, kids and I are already packed in a 740-square-foot house. (To read the whole article, click on link.) http://opinionator.blogs.nytimes.com/2013/04/01/the-ways-ive-worried/

N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society

N30 Pharmaceuticals, Inc., a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis (CF), announced today the presentation of key preclinical data for its novel inhibitors of S-nitrosoglutathione reductase (GSNORi). The data were Continue reading N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society

U.S. FDA OKs Novartis inhaler to treat lung infection in cystic fibrosis patients

U.S. health regulators approved on Friday a hand-held inhaler made by Swiss drug maker Novartis AG to treat a type of bacterial lung infection that often affects cystic fibrosis patients.
Novartis’s TOBI Podhaler contains a dry powder formulation of tobramycin, an antibiotic used to Continue reading U.S. FDA OKs Novartis inhaler to treat lung infection in cystic fibrosis patients